相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。HDAC inhibitors still need a home run, despite recent approval
Malini Guha
NATURE REVIEWS DRUG DISCOVERY (2015)
Epigenetic alterations in acute myeloid leukemias
Parinaz Mehdipour et al.
FEBS JOURNAL (2015)
Differentiation therapy for the treatment of t(8;21) acute myeloid leukemia using histone deacetylase inhibitors
Michael Bots et al.
BLOOD (2014)
Oroxylin A inhibits ATRA-induced IL-6 expression involved in retinoic acid syndrome by down-regulating CHOP
Hui Hui et al.
GENE (2014)
Oroxylin A has therapeutic potential in acute myelogenous leukemia by dual effects targeting PPARγ and RXRα
Hui Hui et al.
INTERNATIONAL JOURNAL OF CANCER (2014)
The Role of Dietary Histone Deacetylases (HDACs) Inhibitors in Health and Disease
Shalome A. Bassett et al.
NUTRIENTS (2014)
Epigenetic modifications: basic mechanisms and role in cardiovascular disease (2013 Grover Conference series)
Joseph Loscalzo et al.
PULMONARY CIRCULATION (2014)
Regulation of STAT signaling by acetylation
Shougang Zhuang
CELLULAR SIGNALLING (2013)
Molecular and Biologic Analysis of Histone Deacetylase Inhibitors with Diverse Specificities
Andrea Newbold et al.
MOLECULAR CANCER THERAPEUTICS (2013)
Histone deacetylase inhibition in the treatment of acute myeloid leukemia: the effects of valproic acid on leukemic cells, and the clinical and experimental evidence for combining valproic acid with other antileukemic agents
Hanne Fredly et al.
CLINICAL EPIGENETICS (2013)
Histone Deacetylase Inhibitors in Cell Pluripotency, Differentiation, and Reprogramming
Androniki Kretsovali et al.
STEM CELLS INTERNATIONAL (2012)
AML1-ETO driven acute leukemia: insights into pathogenesis and potential therapeutic approaches
Megan A. Hatlen et al.
Frontiers of Medicine (2012)
Successful treatment of acute promyelocytic leukemia in a patient on hemodialysis
Yoshiki Tsuchiya et al.
CLINICAL AND EXPERIMENTAL NEPHROLOGY (2011)
Importance of c-kit mutation detection method sensitivity in prognostic analyses of t(8;21)(q22;q22) acute myeloid leukemia
S. Wakita et al.
LEUKEMIA (2011)
Oroxylin A inhibits angiogenesis through blocking vascular endothelial growth factor-induced KDR/Flk-1 phosphorylation
Ying Gao et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2010)
Identification of a myeloid committed progenitor as the cancer-initiating cell in acute promyelocytic leukemia
Florence C. Guibal et al.
BLOOD (2009)
HDAC family: What are the cancer relevant targets?
Olaf Witt et al.
CANCER LETTERS (2009)
Epigenetic modification of CCAAT/enhancer binding protein α expression in acute myeloid leukemia
Bjoern Hackanson et al.
CANCER RESEARCH (2008)
Mechanism for ubiquitylation of the leukemia fusion proteins AML1-ETO and PML-RARα
Oliver H. Kraemer et al.
FASEB JOURNAL (2008)
Histone deacetylase inhibitors: molecular mechanisms of action
W. S. Xu et al.
ONCOGENE (2007)
Novel role of HDAC inhibitors in AML1/ETO AML cells: activation of apoptosis and phagocytosis through induction of annexin A1
Y. Tabe et al.
CELL DEATH AND DIFFERENTIATION (2007)
Oridonin, a diterpenoid extracted from medicinal herbs, targets AML1-ETO fusion protein and shows potent antitumor activity with low adverse effects on t(8;21) leukemia in vitro and in vivo
Guang-Biao Zhou et al.
BLOOD (2007)
Inhibition of histone deacetylase activity by valproic acid blocks adipogenesis
DC Lagace et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
The 8; 21 translocation in leukemogenesis
LF Peterson et al.
ONCOGENE (2004)
The histone deacetylase inhibitor valproic acid selectively induces proteasomal degradation of HDAC2
OH Krämer et al.
EMBO JOURNAL (2003)
Characteristics of t(8;21) acute myeloid leukemia (AML) with additional chromosomal abnormality: concomitant trisomy 4 may constitute a distinctive subtype of t(8;21) AML
K Nishii et al.
LEUKEMIA (2003)
Histone deacetylases (HDACs): characterization of the classical HDAC family
AJM De Ruijter et al.
BIOCHEMICAL JOURNAL (2003)
The myeloid master regulator transcription factor PU.1 is inactivated by AML1-ETO in t(8;21) myeloid leukemia
RK Vangala et al.
BLOOD (2003)
Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen
CJ Phiel et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Rapid induction of histone hyperacetylation and cellular differentiation in human breast tumor cell lines following degradation of histone deacetylase-1
Q Zhou et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2000)
分享论文
